Serum IL-1β and IL-17 levels in patients with COPD: associations with clinical parameters

• Main Authors: Zou Y, Chen X, Liu J, Zhou DB, Kuang X, Xiao J, Yu Q, Lu XX, Li W, Xie B, Chen Q
• Format: Article
• Language: English
• Published: Dove Medical Press 2017-04-01
• Series: International Journal of COPD
• Subjects: IL-1β; IL-17; COPD; clinical parameters; exacerbation
• Online Access: https://www.dovepress.com/serum-il-1beta-and-il-17-levels-in-patients-with-copd-associations-wit-peer-reviewed-article-COPD

Yong Zou,1 Xi Chen,1 Jie Liu,2 Dong bo Zhou,1 Xiao Kuang,1 Jian Xiao,1 Qiao Yu,1 Xiaoxiao Lu,1 Wei Li,1 Bin Xie,1 Qiong Chen1 1Department of Geriatrics, Respiratory Medicine, Xiangya Hospital of Central South University, 2Department of Emergency, The First People’s Hospital of Changsha, Changsha, People’s Republic of China Abstract: COPD is a chronic airway inflammatory disease characterized mainly by neutrophil airway infiltrations. Interleukin (IL)-1β and IL-17 are the key mediators of neutrophilic airway inflammation in COPD. This study was undertaken to evaluate the serum IL-1β and IL-17 levels and associations between these two key mediators with clinical parameters in COPD patients. Serum samples were collected from 60 COPD subjects during the acute exacerbation of COPD, 60 subjects with stable COPD and 40 healthy control subjects. Commercial enzyme-linked immunosorbent assay kits were used to measure the serum IL-1β and IL-17 concentrations. The association between serum IL-1β and IL-17 with FEV1% predicted, C-reactive protein, neutrophil percentage and smoking status (pack-years) was assessed in the COPD patients. We found that serum IL-1β and IL-17 levels in acute exacerbation of COPD subjects were significantly higher than that in stable COPD or control subjects and were positively correlated to serum C-reactive protein levels, neutrophil % and smoking status (pack-years) but negatively correlated with FEV1% predicted in COPD patients. More importantly, serum IL-1β levels were markedly positively associated with serum IL-17 levels in patients with COPD (P=0.741, P<0.001). In conclusion, elevated serum IL-1β and IL-17 levels may be used as a biomarker for indicating persistent neutrophilic airway inflammation and potential ongoing exacerbation of COPD. Keywords: neutrophilic airway inflammation, cigarette smoking, exacerbation